India-based Brassica Pharma is voluntarily recalling four eye ointment products after an FDA inspection found a “lack of sterility assurance at the facility,” the agency said, adding that patients might experience eye infections. In addition to the two national retailers, AACE Pharmaceuticals has also stopped distributing the products.
As of Feb. 16, Brassica Pharma has not received any adverse event reports.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.